Image source: Unsplash/Louis Reed

News • IgM/IgG identification

Coronavirus antibody test in development

In response to the global COVID-19 pandemic, Beckman Coulter announced that it is developing assays to identify IgM and IgG antibodies to the coronavirus or SARS-CoV-2.

The assays will be designed for use on any of its high-throughput Access family of immunoassay systems, including the Access 2 and DxI series installed globally. Research has shown that after infection with SARS-CoV-2, viral antigens stimulate the body’s immune system to produce antibodies that can be detected with IgM and IgG tests. “Antibody assays play a critical role in understanding the measure of immunity an individual has developed against SARS-CoV-2,” said Kathleen Orland, senior vice president and general manager for Beckman Coulter’s chemistry and immunoassay business. “This type of understanding could help determine the identification of those who would require a vaccine once available or when an infected individual could safely return to work.”

This test could allow those without immunity to be identified and kept safe until the pandemic subsides

Shamiram R. Feinglass

“With the ability to assess a patient’s immunity to SARS-CoV-2, this testing modality may enable clinicians to clear hospital staff, emergency responders, and others to get back to work with an indication that have had prior exposure and therefore may have immunity to the disease,” said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. “This test also could allow those without immunity to be identified and kept safe until the pandemic subsides.”

Once the assays are finalized, Beckman Coulter intends to follow FDA’s Emergency Use Notification process as provided in the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency (March 16, 2020). For the latest information on the new assays, visit www.beckmancoulter.com/coronavirus 


Source: Beckman Coulter

01.04.2020

Read all latest stories

Related articles

Photo

Sponsored • Infection management

New sepsis marker speeds up detection and therapy

Sepsis is the cause of one in five deaths worldwide, killing nearly 11 million people each year, many of them children. It is also a major cause of disability, affecting millions more. To combat the…

Photo

Interview • Urinalysis for Covid-19 diagnostics

Automation to relieve pandemic pressure from laboratories

To provide a solution for the challenges of the coronavirus pandemic, Beckman Coulter recently launched the DxU Iris, a urinalysis solution which aims to improve lab workflows.

Photo

Sponsored • Lab equipment

Minimising laboratory errors with automation

Staffing shortages, increased testing volumes and the need to improve turnaround times have led to labs seeking to streamline services. Automation is the key, thanks to the role it plays in…

Related products

Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter – AU5800 Series

Clinical Chemistry

Beckman Coulter – AU5800 Series

Beckman Coulter Diagnostics
Beckman Coulter  – AutoMate 2500 Family Sample Processing Systems

Sample Processing

Beckman Coulter – AutoMate 2500 Family Sample Processing Systems

Beckman Coulter Diagnostics
Beckman Coulter – Diazyme Human Kappa & Lambda FLC assays

Clinical Chemistry

Beckman Coulter – Diazyme Human Kappa & Lambda FLC assays

Beckman Coulter Diagnostics
Subscribe to Newsletter